Osteoclast bone resorption pathway

The osteoclast bone resorption pathway is a critical physiological process responsible for the breakdown of bone matrix and the release of minerals into the blood [1.2.1, 1.5.3]. This process is mediated by osteoclasts, large multinucleated cells derived from the monocyte-macrophage lineage [1.5.1, 1.5.3]. Key molecular drivers include the RANKL/RANK/OPG signaling axis, which regulates osteoclast differentiation and survival, and enzymes like Cathepsin K and the V-ATPase proton pump, which facilitate the degradation of the organic and inorganic components of bone [1.2.3, 1.5.2]. Dysregulation of this pathway, typically characterized by excessive osteoclast activity, leads to skeletal diseases such as osteoporosis, Paget's disease, and bone metastases [1.1.2, 1.3.4]. Therapeutic strategies targeting this pathway include bisphosphonates, which induce osteoclast apoptosis, and denosumab, a monoclonal antibody that inhibits RANKL [1.3.1, 1.3.5]. While effective in increasing bone mineral density and reducing fracture risk, these therapies are associated with specific safety concerns like osteonecrosis of the jaw and atypical femoral fractures [1.1.3, 1.1.4].

Other names

OsteoclastogenesisBone remodelingBone turnoverBone resorption

Drugs targeting this pathway work by inhibiting osteoclast differentiation, activity, or survival. RANKL inhibitors (e.g., denosumab) prevent the maturation of osteoclast precursors [1.3.1, 1.5.2]. Bisphosphonates bind to hydroxyapatite and are internalized by osteoclasts, where they disrupt farnesyl pyrophosphate synthase (FPPS) or induce apoptosis [1.3.1, 1.3.5]. Calcitonin directly inhibits osteoclast activity via its receptor [1.3.3, 1.5.3]. Cathepsin K inhibitors prevent the enzymatic degradation of the bone matrix [1.2.3, 1.5.4].